PT - JOURNAL ARTICLE AU - Chapman, Lloyd A. C. AU - Shukla, Poojan AU - Rodríguez-Barraquer, Isabel AU - Shete, Priya B. AU - León, Tomás M. AU - Bibbins-Domingo, Kirsten AU - Rutherford, George W. AU - Schechter, Robert AU - Lo, Nathan C. TI - Risk factor targeting for vaccine prioritization during the COVID-19 pandemic AID - 10.1101/2021.03.04.21251264 DP - 2022 Jan 01 TA - medRxiv PG - 2021.03.04.21251264 4099 - http://medrxiv.org/content/early/2022/01/07/2021.03.04.21251264.short 4100 - http://medrxiv.org/content/early/2022/01/07/2021.03.04.21251264.full AB - A key public health question during any disease outbreak when limited vaccine is available is who should be prioritized for early vaccination. Most vaccine prioritization analyses only consider variation in risk of infection and death by a single risk factor, such as age. We provide a more granular approach with stratification by demographics, risk factors, and location. We use this approach to compare the impact of different COVID-19 vaccine prioritization strategies on COVID-19 cases, deaths and disability-adjusted life years (DALYs) over the first 6 months of vaccine rollout, using California as a case example. We estimate the proportion of cases, deaths and DALYs averted relative to no vaccination for strategies prioritizing vaccination by a single risk factor and by multiple risk factors (e.g. age, location). We find that age-based targeting averts the most deaths (62% for 5 million individuals vaccinated) and DALYs (38%) of strategies targeting by a single risk factor and targeting essential workers averts the least deaths (31%) and DALYs (24%) over the first 6 months of rollout. However, targeting by two or more risk factors simultaneously averts up to 40% more DALYs. Our findings highlight the potential value of multiple-risk-factor targeting of vaccination against COVID-19 and other infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funding from the California Department of Public Health. NCL is supported by the University of California, San Francisco (Department of Medicine). This work represents the viewpoints of the authors alone and not necessarily those of the California Department of Public Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of California, San Francisco Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analysis code is available online at https://github.com/LloydChapman/COVIDVaccineModelling. The California Department of Public Health case data required for fitting the Poisson regression model contain personally identifiable information and therefore cannot be made freely available. Individuals interested in accessing the data should contact the California Department of Public Health. The simulated population data required to run the vaccine prioritization simulations is available at http://doi.org/10.5281/zenodo.4516526.https://github.com/LloydChapman/COVIDVaccineModellinghttp://doi.org/10.5281/zenodo.4516526